Biopharmaceutical company Alector Inc. announced that it will discontinue its Phase II PROGRESS-AD clinical trial of its candidate drug Nivisnebart (development code AL101/GSK4527226) for the treatment of early-stage Alzheimer's disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ampco-Pittsburgh Publishes Q3 2026 Earnings Call Transcript
Nvidia's newly appointed Chairman of the Board addresses all employees: The company's strength comes from its team, technology, and ecosystem.
In an email, NVIDIA's new Chairman of the Board Harvey Jones stated that the board takes its duty as guardian of this great company very seriously. The company's strength comes from our employees, leadership team, technological capabilities, and partner ecosystem. We will continue to drive business growth and lead the industry forward. Thank you all for your focus, professionalism, and dedication to NVIDIA.
Crypto prices
More
